Skip to main content
Smart Investors Daily
AP

NASDAQ · APLMW

Apollomics, Inc.

Financial Services · Financial - Conglomerates

$0.02

Down-$0.00 (-0.55%)

Updated Aug 17, 2026, 8:33 AM

SID Score

5.0/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
175.88M
P/E ratio
-0.71
Dividend yield
0.00%
52-week range
$0.01 – $0.23
Volume
400
Avg. volume
89.53K

Price performance

APLMW price history

1M range · 0 trading sessions · Daily adjusted prices

APLMW does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest APLMW news

The latest Smart Investors Daily articles mentioning APLMW.

APLMW research

Overview

Company profile and research snapshot.

Company profile

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

ChartMill · Jul 15, 2026

These stocks are moving in today's session

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.